Target intelligence / Profile preview

G inhibitory and G o proteins (Gi/o)

Target
Gi/o
Molecular classification
G protein, Intracellular signaling protein, Other
01

Overview

G inhibitory and G o proteins (Gi/o) are a major subfamily of heterotrimeric G proteins that act as critical intracellular transducers downstream of G protein-coupled receptors (GPCRs). Upon activation by GPCRs, Gi/o proteins dissociate into Gαi/o and Gβγ subunits, which inhibit adenylyl cyclase to decrease intracellular cyclic AMP (cAMP) levels and modulate various effectors, including G protein-coupled inwardly rectifying potassium (GIRK) channels and voltage-gated calcium channels. These proteins play essential roles in regulating neuronal excitability, heart rate, and hormone secretion. Dysregulation of Gi/o protein signaling is implicated in several diseases, including cancer progression, chronic pain, neurodegenerative disorders, and movement disorders such as GNAO1 encephalopathies. Pharmacological modulation of Gi/o proteins can be achieved directly using tools like pertussis toxin, which inactivates them via ADP-ribosylation, or mastoparan, which directly activates them. Developing selective small-molecule inhibitors of Gi/o proteins represents a promising therapeutic strategy to overcome GPCR redundancy in cancer and treat rare genetic encephalopathies.

Other names
Gi/o proteinsG inhibitory and G other proteinsG inhibitory/other G proteinsGi/o family G proteinsGi/o G-proteinsG inhibitory and G o familyG inhibitory and G o subunits
02

Mechanism of action

ADP-ribosylation and inactivation of Gi/o proteins, direct receptor-independent activation of Gi/o proteins, inhibition of Gβγ subunit signaling, competitive inhibition of Gαi protein-protein interactions, or inhibition of GTP binding and nucleotide exchange.

03

Biological functions

Signal transductionRegulation of heart rateRegulation of neuronal excitabilityRegulation of hormone secretionInhibition of adenylyl cyclaseOther
04

Disease associations

CancerNeurodegenerative diseaseCardiovascular diseaseInfectionOther
05

Safety considerations

Broad physiological disruption due to ubiquitous expressionCardiovascular side effects (e.g., bradycardia, arrhythmia)Neurological side effects (e.g., altered pain perception, motor dysfunction)Endocrine disruption (e.g., altered hormone secretion)Lack of highly selective small-molecule modulators
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

cAMP levelsGIRK channel activityGαi/o protein expressionPhospho-ERK1/2 levelsPhospho-AKT levels

Beyond the preview

Go deeper on G inhibitory and G o proteins (Gi/o).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on G inhibitory and G o proteins (Gi/o).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call